PURPOSE: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an immune-mediated disease of the central nervous system (CNS). The aim of this study was to describe the variability of clinical presentation in anti-NMDAR encephalitis, treatment and outcomes in a case series of children and adolescents. METHODS: Retrospectively analyse patients diagnosed with anti-NMDAR encephalitis, from 2010 to 2018. RESULTS: The study population consisted of nine children with anti-NMDAR encephalitis from southern Brazil, six females and three males, aged 5 months to 16 years (mean 5 years). The time of follow-up varied between 1 and 7 years, with a mean of 3 years. The most frequent first manifestation consisted of seizures. All patients described had psychiatric symptoms and a wide spectrum of neurologic findings. Five patients had unilateral symptoms. Magnetic resonance imaging and electroencephalogram were normal in most patients. Cerebrospinal fluid pleocytosis occurred in five patients. All patients were administered immunoglobulin and/or steroids. Seven patients (78%) required cyclophosphamide and/or rituximab. Almost half of the patients fully recovered from all symptoms. CONCLUSIONS: A wide variety of symptoms were observed in this study and, although unilateral symptoms are rarely reported in the literature, a high frequency was observed among Brazilian children. Alternatives to first-line therapy should be considered in patients with clinical suspicion, even if they have not had a good response with first-line therapy.
PURPOSE: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an immune-mediated disease of the central nervous system (CNS). The aim of this study was to describe the variability of clinical presentation in anti-NMDAR encephalitis, treatment and outcomes in a case series of children and adolescents. METHODS: Retrospectively analyse patients diagnosed with anti-NMDAR encephalitis, from 2010 to 2018. RESULTS: The study population consisted of nine children with anti-NMDAR encephalitis from southern Brazil, six females and three males, aged 5 months to 16 years (mean 5 years). The time of follow-up varied between 1 and 7 years, with a mean of 3 years. The most frequent first manifestation consisted of seizures. All patients described had psychiatric symptoms and a wide spectrum of neurologic findings. Five patients had unilateral symptoms. Magnetic resonance imaging and electroencephalogram were normal in most patients. Cerebrospinal fluid pleocytosis occurred in five patients. All patients were administered immunoglobulin and/or steroids. Seven patients (78%) required cyclophosphamide and/or rituximab. Almost half of the patients fully recovered from all symptoms. CONCLUSIONS: A wide variety of symptoms were observed in this study and, although unilateral symptoms are rarely reported in the literature, a high frequency was observed among Brazilian children. Alternatives to first-line therapy should be considered in patients with clinical suspicion, even if they have not had a good response with first-line therapy.
Authors: Ethan G Hughes; Xiaoyu Peng; Amy J Gleichman; Meizan Lai; Lei Zhou; Ryan Tsou; Thomas D Parsons; David R Lynch; Josep Dalmau; Rita J Balice-Gordon Journal: J Neurosci Date: 2010-04-28 Impact factor: 6.167
Authors: Felippe Borlot; Mara Lucia F Santos; Marcia Bandeira; Paulo B Liberalesso; Fernando Kok; Alfredo Löhr; Umbertina C Reed Journal: J Pediatr (Rio J) Date: 2012-03-28 Impact factor: 2.197
Authors: Josep Dalmau; Erdem Tüzün; Hai-yan Wu; Jaime Masjuan; Jeffrey E Rossi; Alfredo Voloschin; Joachim M Baehring; Haruo Shimazaki; Reiji Koide; Dale King; Warren Mason; Lauren H Sansing; Marc A Dichter; Myrna R Rosenfeld; David R Lynch Journal: Ann Neurol Date: 2007-01 Impact factor: 10.422
Authors: Julia Granerod; Helen E Ambrose; Nicholas Ws Davies; Jonathan P Clewley; Amanda L Walsh; Dilys Morgan; Richard Cunningham; Mark Zuckerman; Ken J Mutton; Tom Solomon; Katherine N Ward; Michael Pt Lunn; Sarosh R Irani; Angela Vincent; David Wg Brown; Natasha S Crowcroft Journal: Lancet Infect Dis Date: 2010-10-15 Impact factor: 25.071
Authors: Russell C Dale; Sarosh R Irani; Fabienne Brilot; Sekhar Pillai; Richard Webster; Deepak Gill; Bethan Lang; Angela Vincent Journal: Ann Neurol Date: 2009-11 Impact factor: 10.422
Authors: T Iizuka; F Sakai; T Ide; T Monzen; S Yoshii; M Iigaya; K Suzuki; D R Lynch; N Suzuki; T Hata; J Dalmau Journal: Neurology Date: 2007-09-26 Impact factor: 9.910
Authors: Nicole R Florance; Rebecca L Davis; Christopher Lam; Christina Szperka; Lei Zhou; Saba Ahmad; Cynthia J Campen; Heather Moss; Nadja Peter; Amy J Gleichman; Carol A Glaser; David R Lynch; Myrna R Rosenfeld; Josep Dalmau Journal: Ann Neurol Date: 2009-07 Impact factor: 10.422
Authors: Daniel Almeida do Valle; Mara Lúcia Schmitz Ferreira Santos; Michelle Silva Zeny; Mara L Cordeiro Journal: Front Neurol Date: 2020-10-26 Impact factor: 4.003